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ABSTRACT
Radiation protection standards for space activities differ substantially from those applied to
terrestrial working situations. The levels of radiation and subsequent hazards to which space
workers are exposed are quite unlike anything found on earth. In view of these considerations,
NASA has adopted a more highly refined system of risk management than that conventionally
applied to radiation workers. The refined system involves assessing the risks to each space worker
from all sources of radiation (occupational and non-occupational) at the organ level. In this study
we applied risk coefficients in the National Council on Radiation Protection and Measurements
(NCRP) Report 98, to previous space and medical exposures in order to estimate the
radiation-induced lifetime cancer incidence and mortality risks to 19 representative space workers.
Results indicate a per capita (n=19) radiation-induced cancer incidence risk from space activities,
diagnostic X-ray, and nuclear medicine procedures of 3.1 x 10-s, 37.9 x 10-5, and 6.8 x 10-5,
respectively. For radiation-induced cancer mortality, the per capita risks were 2.1 x 10-s, 22.7 x
10-s, and 4.9 x 10-5, respectively. At present, the risk from medical procedures when compared to
space activities is 14 times higher for cancer incidence and 13 times higher for cancer mortality;
however, this will change as the per capita dose during Space Station Freedom and interplanetary
missions increases and more is known about the risks from exposure to high-LET radiation. The
per capita effective dose equivalents (HE) from space activities, diagnostic X-ray, and nuclear
medicine procedures were 1.51 mSv (151 totem), 15.9 mSv (1590 totem), and 3.6 mSv (360 mrem).
Mortality estimates based on risk coefficients in Publication 26 of the International Commission on
Radiological Protection (ICRP) underestimated NCRP-based mortality estimates from space
activities and diagnostic X-ray by 17% and 28%, respectively, and overestimated mortality risk
from nuclear medicine procedures by 3%. Two units, the Incidence Risk Unit (IRU x 10 -s) and the
Mortality Risk Unit (MRU x 10 -5) for radiation protection, are introduced.
INTRODUCTION
Radiation protection standards for space activities are very different form those applied to
terrestrial situations. The levels and mixed fields of radiations to which astronauts are exposed are
unlike anything found on earth. During low-earth orbit (LEO) missions, such as those previously
flown by Mercury, Gemini, and those currently flown by Shuttle, geomagnetically trapped protons
with energies on the order of 30 to 500 MeV are of interest. For exploratory class missions, such as
the lunar missions of Apollo and future missions to Mars, interest is directed toward galactic cosmic
rays (GCR) whose energies range from 30 MeV to 10 GeV. In addition, there is the potential for
large solar particle events, during which a large plasma of protons and helium ions is ejected into
the near-earth vicinity. Each mission scenario is characterized by a unique level and mixture of
radiations. Figure 1 shows an outline of the particulate space radiation environment characterizing
the flux and energy of particles. Perhaps as equally important as the above radiations are the
secondary particles produced from their interactions with spacecraft materials and body tissues.
Traditionally, the system of dose limitations introduced by the International Commission on
Radiological Protection (ICRP) has been a convenient method for limiting the risks to which
radiation workers are exposed (1). A fundamental principle on which this system is based is that
risk is directly proportional to effective dose equivalent (HE). As such, HE serves as a surrogate for
risk. We shall not be concerned with this type of approach, but rather one in which individual
risks are limited by actual estimates of lifetime risk based on organ doses and the most complete
age-, sex-, and site-specific lifetime risk information. In recent years a similar approach has
received particular attention, the most notable of which was the development of
radioepidemiological tables for use in determining the probability of causation (PC) (2). The PC is
defined as the probability that a given dose of radiation will cause cancer at a given age following
exposure.
The National Council on Radiation Protection and Measurements (NCRP) in its Report 98 has
recommended that NASA adopt a system of risk limitations that is based on a radiation-induced
lifetime mortality risk of 3% from occupationai radiation exposure (3). The recommended career
limits take into account the sex of each individual and their age at first flight. Figure 2 shows the
career limit (Sv) as a function of age at first flight for males and females. Also given in Report 98
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Figure I. The particulate space radiation environment.
are age- and sex-specific lifetime risk coefficients for cancer incidence and mortality from
exposure to low linear energy transfer (LET) radiation for the following sites: lung, breast, thyroid,
esophagus, stomach, colon, liver, pancreas, kidney, bladder, acute leukemia, chronic granulocytic
leukemia, and an aggregate of "other" tissues consisting of the oral cavity, rectum, gall bladder,
uterus, ovaries, brain, bone, prostate, and testes, shown in Tables 1 and 2. The likelihood of
radiation-induced lymphoma and Hodgkin's disease was also considered in the "other" tissues. Risk
coefficients for all sites were based on the linear-quadratic relationship except for the breast and
thyroid for which the linear model was more appropriate. The multiplicative (relative risk) model
was used in developing lifetime r_k coefficients for all sites except leukemia for which the additive
(absolute risk) model provided a better fit.
This paper addresses the projection of radiation-induced lifetime cancer incidence and
mortality risks for astronauts who were previously exposed to space radiation and medical
procedures using the NCRP risk coefficients in Tables 1 and 2. A comparison is made between the
NCRP-based results and mortality risks based on ICRP recommendations. The units for
radiation-induced lifetime cancer incidence and mortality risk were the incidence risk unit (IRU x
10-6) and mortality risk unit (MRU x 10-s), respectively. The per capita IRU and MRU from
space activities and medical procedures were estimated for astronauts who have previously flown on
LEO Shuttle missions and undergone medical radiodiagnoses. Also estimated were the per capita
H_, normalized somatic effective dose equivalent (Hp.,Ns), and weighted dose (Sj) for comparison
(4,5).
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Figure 2. Age- and sex-specific career dose equivalent limits for space activities.
METHODS
EXPOSURE HISTORY DATA BASE
NASA has maintained, as part of its radiation protection program, archives of astronaut
radiation exposure histories since Project Mercury (6,7,8,9,10,11,12,13). Exposure records in this
computerized data base are divided into several groups representing space activities, diagnostic
x-ray examinations, and nuclear medicine procedures. Archived data for space activities include
the individual's name, age, sex, age at exposure, launch date, vehicle, mission duration (h), altitude
(km), inclination (deg), the radiation absorbed dose (mGy) from thermoluminescent dosimetry
(TLD), and organ dose equivalents (mSv) for each mission. Diagnostic x-ray examination data
include the individual's name, age, sex, age at exposure, date, type of projection, number of films,
projection view (PA, AP, LAT or OBLQ), tube potential (kVp), filament current (mA), skin
entrance exposure (mR), half-value layer (mm AI), total filtration (mm A1), source-to-image
receptor distance (era), and horizontal and vertical film size (cm). Records from nuclear medicine
studies involving the use of radionuclides include the following data: name, age, sex, age at
exposure, date, type of procedure, administered radioactivity (MBq), isotope, and the chemical form
of the labelled compound (14).
ORGAN DOSE EQUIVALENTS FROM SPACE ACTIVITIES
The charged-particle radiations of primary interest for LEO missions are protons and GCR.
The dose deposition from protons is delivered at a rate that is inversely proportional to particle
energy, until a maximum, known as the Bragg peak is reached (15). The dose deposition from
GCR is very similar to that of protons; however, due to the much higher energies of GCR, there is
more potential for inelastic nuclear interactions resulting in fragments whose LET is greater than
that of the incident particle. This combination of incident and secondary radiation results in a
polychromatic omnidirectional species of particles, each of which deposit their energy in a manner
unique to the geometry, shielding, and organ under consideration. A detailed description of the
space radiation environment and relevant dosimetry is given in NCRP Report 98.
Table 1. Predicted lifetime risk of excess cancers among 1000
persons who experienced a protracted exposure of 10 rad within
1 year by age at exposure, sex, and specific organ.
ARE AT
$EX EXPOSURE LUNG BREAST THYROID ESOPHAG. STOMACH COLON LIVER
MALE 25 0,93 0.25 0.06 0.49 0.40 0.42
35 0.63 0.18 0.03 0.25 0.19 0.14
45 0,45 0.11 0.02 0.16 O. 11 0.08
55 0.33 0.06 0.03 0.15 0.10 0.04
FEMALE 25 0,74 3.12 0.77 0.07 0.69 0.48 O.50
35 0.61 1.02 0,56 0.04 0.40 0.24 0.21
45 0.55 0.34 0.40 0.03 0.25 0,14 O.10
55 0.47 0.17 0,27 0.04 0.21 O, 14 0.05
ALL CHRON. SUM OF ALL
ARE AT KIDNEY & ACUTE GRANULO. NON'CLL OTHER TOTAL
SEX EXPOSURE PANCR. BLADDER LEUKEMIA LEUKEMIA LEUKEMIA CANCERS CANCER
MALE 25 0.29 0,29 O.14 0.08 O,21 O.68 4.03
35 0.14 0.16 O.15 0.08 0.23 0,31 2.23
45 0.0_ 0.10 0,17 0.O8 0.25 0.16 1.51
65 0.09 0.O8 0.17 0.08 0.25 0.13 1.25
FEMALE 25 0.45 0.34 0.09 0.05 O.14 0.44 7.73
35 0,19 0.20 0.10 0.06 0.16 0.25 4.78
45 0.12 0.14 0.13 O.06 O.19 0.18 2,45
55 0,12 0.11 O.15 0.06 0.21 0.16 1.86
EXPOSURE: PROTRACTED (¢0.O5 Gy/d)
TYPE OF RISK: INCIDENCE
RADIATION DOSE: O.1 Gy (10 rlld)
DURATION: WITHIN 1 YEAR
SOURCE: NCRP Report 98
Table 2. Predicted lifetime risk of excess cancer deaths among 1000
persons who experienced a protracted exposure of 10 rad within
1 year by age at exposure, sex, and specific organ.
AGE AT
BEX EXPOSURE LUNG BREAST THYROID E|OPHAG. 8TOMACH COLON LIVER
MALE
FEMALE
25 0.73 0.04 0.06 0,34 0.22 0.41
35 0.50 0.03 0.03 0.17 0.10 0.14
46 0,36 0.02 0.02 0.11 0.06 0.06
66 0.2 IS 0.01 0.02 O. 11 0.05 0.0.1
26 0.63 0.99 0.07 0.08 O,51 0.24 0.48
35 0,44 O.81 0.05 0.03 0,30 O.12 0.21
4 S 0.40 O. 11 0.04 O.O2 O. 18 O.O7 O. 10
66 0.34 0.05 0.03 0.03 0,16 0.07 0.06
ALL CHRON. EUM OF ALL
AGE AT KIONEY & ACUTE GRANULO. NON-CLL OTHER TOTAL
BEX EXPOSURE PANCR. BLADDER LEUKEMIA LEUKEMIA LEUKEMIA CANCERS CANCER
MALE 25 0.27 0.09 O.12 0.O6 0,17 0.27 2.60 1
36 0.13 O.OS 0.13 0.06 0,18 0.12 1.43
48 0.08 0.03 0.15 O.OS 0.20 0.06 1,00
86 0.08 0.02 0.15 0.06 0.20 O.O6 0.84
2B 0.42 0.12 0,07 0.03 0.10 0.18 .1.70
36 O. 18 0.07 0.09 0.03 0.12 O.10 2.21
46 0.11 O.OS O.11 0.03 0.14 0.07 1.28
68 O. 11 0.04 0.12 0.03 0.16 0.07 1.08
FEMALE
EXPOSURE: PROTRACTED (40.06 Gy/d)
TYPE OF RISK: MORTALITY
RADIATION DOSE: 0.1 Gy (10 red)
DURATION: WrI'HIN 1 YEAR
IOURCE: NCRP Report 98
Table 3. Organ weighting factors used to estimate HE, and Hz,Ns in this study.
Organ WTa WT,NS b
Ovaries .25 -
Testes .25 -
Breast .15 .19
Red Bone Marrow .12 .16
Lung .12 .16
Thyroid .03 .04
Bone Surfaces .03 .04
Remainder .30 .40
aWelghtin, g factors bued on a total stochastic risk of 1.65 x
lO-Z Sv-_.
bWe]ghting factors based on total somatic risk of 1.25 x 10 -2
Sv'_ normalised to unity.
Estimates of the lifetime risks from cancer incidence and mortality from space activities
required the estimation of organ dose equivalents. Within this framework, we used the
Computerized Anatomical Man (CAM) model to generate body self-shielding data comprised of
information defining the paths traversed by rays traced from internal dose points in the brain,
lenses of the eyes, thyroid, esophagus, marrow, lungs, colon, liver, kidneys, spleen, stomach,
pancreas, bladder, and testes to the exterior surface for 20 exposures to 19 individuals. For each
dose point the mass distribution in the surrounding 4n solid-angle was characterized by
systematically tracing 512 rays (16). Ray-tracing results were processed to characterize the
equivalent aluminum thickness as areal density at each dose point. Areal densities for each dose
point were then coupled with the AP-8 proton environment model (17), CREME GCR model (18),
BRYNTRN baryon transport code (19), and the PDOSE proton dose code to yield radiation
absorbed dose (20). Dose equivalent was determined by applying ICRP LET-dependent quality
factors (1), which are stored within the BRYNTRN and PDOSE codes.
ORGAN DOSE EQUIVALENTS FROM MEDICAL PROCEDURES
Astronauts undergo radiodiagnoses for routine health care and screening during the selection
process in order to be medically qualified for space flight. While radiation protection does not
typically involve individual monitoring for medical exposures, we considered risk from all sources
and thus needed to account for such exposures. Estimates of risk from 364 diagnostic x-ray
exposures to the same 19 individuals were based on organ dose equivalents, which were estimated
as follows: For diagnostic x-ray examinations performed locally, for which the exposure settings
and calibration-obtained beam qualities were known, a computer program (21) was used to
estimate the radiation absorbed dose to the following organs: testes, marrow, lung, thyroid, bone,
bladder, colon, kidneys, liver, uterus, braln, and lenses of the eyes. The following examination
parameters were specified at run-time: projection and view (PA, AP, LAT), x-ray field size at the
image receptor, x-ray field location in relation to anatomical landmarks, skin entrance exposure
(mR), beam quality (kVp and HVL-I), and source-to-image receptor distance (cm). Skin entrance
exposure (mR) and total tube filtration (ram A1) were calculated using published exposure values
(22). For x-ray examinations performed at locally referred institutions, we used the the same
computer program for estimating organ doses, but derived entrance skin exposure and peak
kilovoltage by combining exposure values and beam qualities (HVL-I) for projections common in
diagnostic radiology (23). For nuclear medicine procedures, organ dose conversion factors
(mGy/MBq) were used to obtain dose equivalent to the adrenals, bladder, bone, stomach, small
intestine, upper large intestine, lower large intestine, kidneys, liver, lungs, pancreas, marrow,
spleen, testes, thyroid, and other organs for 65 exposures to 4 individuals (24).
ESTIMATIONOF H E, HE,NS, S:, AND LIFETIME RISKS FROM EXPOSURE TO SPACE
RADIATIONS, DIAGNOSTIC X-RAY E.XAMINATIONS, AND NUCLEAR MEDICINE
PROCEDURES
After estimating organ dose equivalents from space activities and medical procedures, several
estimators representing the detriment from radiation exposure were calculated. First, the effective
dose equivalent (HE_ was estimated to assess the stochastic risk to space workers from medical
exposures. The Intei'national Commission on Radiological Protection (25) introduced HE for the
protection of workers. HE includes the genetic and somatic risk for a theoretically
age-independent and sex-independent population that is occupationally exposed to radiation; it can
be used to equate harm (somatic and genetic risk) from a nonuniform exposure to harm from a
uniform whole-body exposure. It does not include the genetic detriment of generations
subsequent to the second generation, nor does it include nonfatal malignancies (cancer incidence).
For somatic detriment, the normalized somatic effective dose equivalent (Hv_,Ns) was used. The
HE Ns was introduced to measure somatic detriment to a patient, because the age distribution of
patients undergoing rad_odmgnostic procedures _s not normally distributed and _s skewed toward
older ages when the birth-rate is low (4,26,27). We have employed this somatic-based derivative
as part of a more refined approach to counseling, which involves separate somatic and genetic risk
(offspring) assessments. The weighting factors used to estimate HE and HE,NS are shown in Table
3.
Table 4. Male and female age- and sex-dependent
ponderation factors used to calculate Sj.
Age at irradiation
Sex Organ 25 35 45 55
Male Testes 0.47 0.10 0.02 0.00
Marrow 0.12 0.12 0.12 0.09
Lung 0.12 0.10 0.07 0.04
Thyroid 0.03 0.03 0.02 0.01
Bone 0.03 0.03 0.02 0.01
Remainder 0.28 0.24 0.18 0.10
Female Ovaries 0.30 0.05 0.00 0.00
Breast 0.33 0.31 0.28 0.22
Marrow 0.12 0.12 0.12 0.11
Lung O.12 O.I0 0.07 0.04
Thyroid 0.03 0.03 0.02 0.01
Bone 0.03 0.03 0.02 0.01
Remainder 0.28 0.24 0.18 0.10
* Ponderation factor. _ on • total itoc.huti¢ riJk of 1.65 x 10-2 Sv-l.
To provide a measure of detriment for space activities and medical procedures based on sex
and age, the age- and sex-specific weighted dose (Sj) was used. Beninson and Sowby introduced
Sj along with its age- and sex-dependent ponderation factors (Table 4) for weighting detriment
from medical irradiation (5). In previous work, Mettler et al. used these age- and sex-dependent
ponderation factors to compare HE to Sj and found that their use results in a reduction in the
estimate of detriment by 33% to 50% (28,29).
Lastly, we estimated the per capita lifetime risk of radiation-induced cancer incidence and
mortality from exposure to LEO space radiations and medical procedures by multiplying the
organ-, age-, and sex-specific risk coefficients in Tables I and 2 by the organ dose equivalents
from each exposure. This yielded the Incidence Risk Unit (IRU x 10-s) and Mortality Risk Unit
(MRU x 10 -s) for each organ. To illustrate the refined system, estimates of per capita IRU,
6
MRU, Hw, Hz,Ns, and Sj were made for 19 males who have flown previously on Shuttle and
undergone radiodiagnoses. The Append'ix lists the equations used for calculating HE, H_.,NS, Sj,
IRU, and MRU.
RESULTS AND DISCUSSION
COMPARISON OF DETRIMENT FROM SPACE ACTIVITIES AND MEDICAL EXPOSURES
Table 5 gives the per cent contribution of the weighted dose equivalents to HE, HE,NS, and Sj
from space activities, diagnostic X-ray, and nuclear medicine procedures. In all three cases, the
remainder tissue contributed to more than 30% of HE. This corroborates several recent studies on
contribution of the remainder to HE (30,31). Figures 3,4, and 5 depict graphically the
contribution of the weighted dose equivalents to HE, H_.,Ns, and Sj for the three sources in Table
5. It should be noted that the highest per cent contribution to Hz, Hz.Ns, and Sj was from the
remainder tissue, followed by the testes for Hz and the marrow for Sj (Fig. 3,4,5). This indicates
clearly that the remainder tissues accounted for the largest proportion of mortality risk. It can be
argued, therefore, that the concept of an effective dose should not include a remainder organ for
which the aggregate of risk from other organs is considered.
Table 5. Per cent contribution of weighted dose equivalents to
HE Hz Ns, and S. from space activities (n=20), diagnostic
X-ray (n=364), and nuclear medicine procedures (n=65).
Source Organ HE HE,NS Sj
Space activities Testes 29 5
Marrow 14 2() 26
Lung 14 20 16
Thyroid 4 5 5
Bone 4 5 6
Remaindera 35 50 42
Diagnostic x-ray
examinations
Testes 38 - 27
Marrow 7 11 10
Lung 14 23 17
Thyroid 5 9 8
Bone 6 9 8
Remainderb 30 48 32
Nuclear medicine
procedures
Testes 14 - 2
Marrow 17 20 26
Lung 13 15 13
Thyroid 3 2 3
Bone 3 3 4
Remainder: 50 60 52
• Organs considered in the remainder were bladder, colon, stomach, kidneys, fiver, esophagus, pancreas, spleen, brain, and
imum of eyes.
b Organs considered in the remainder were bladder, colon, small intestine, kidneys, liver, brain, and lenses of eyes.
c Organs considered in the remainder were bladder, upper large intestine, lower large intestine, small intestine, stomach,
kidneys, fiver, spleen, adrenals, pancreas, brain, and lento of eyes.
Per capita values for H E, HE,NS, Sj, IRUs, and MRUs for space activities and medical
procedures are shown in Table 6, which illustrates that the per capita HE, HE,NS , Sj, IRU, and
MRU (NCRP- and ICRP-based) from medical procedures were 12 to 17 times greater than that for
space activities. The per capita HE from space activities, diagnostic X-ray, and nuclear medicine
procedures were 1.51 mSv (151 torero), 15.9 mSv (1590 mrem), and 3.6 mSv (360 mrem),
respectively. In particular, HE from space activities was comparatively higher than the per capita
radiation absorbed dose from space activities of 0.95 mGy (95 mrad). Medical procedures, for the
19 individuals under study, contributed on average to 93% of the total risk, which suggests that the
risks from medical procedures far outweighed the risks from space activities. The per capita H_.
from space activities and diagnostic X-ray (Table 7) was 6% and 17% greater than HE,NS for the
same sources. However, an opposite trend was discovered for nuclear medicine procedures (13%
lower), which is explained by the small contribution (14%) of the weighted gonad dose equivalent to
HE. For space activities, diagnostic x-ray examinations, and radionuclide procedures, HE yielded a
detriment that was 48%, 31%, and 37% higher than detriment measured by Sj, respectively. This is
in good agreement with the findings of Mettler et al. (28).
The ICRP-based risk estimates underestimated NCRP-based mortality estimates from space
activities and diagnostic X-ray by 17% and 28%, respectively, and overestimated mortality risk
from nuclear medicine procedures by 3%. There were several reasons for this: for space activities
and diagnostic X-ray, mortality risk, as defined by the ICRP (ICRP77), is lower than mortality
based on NCRP risk coefficients. Further, in the NCRP methodology, the remainder or other tissue
does not contain organs such as the colon, kidneys, bladder, liver, etc., which are included in the
ICRP's remainder. Since the remainder tissue accounted for 60% of HE,NS from nuclear medicine
procedures, the ICRP-based estimates did not underestimate NCRP-based risk.
Table 6. Per capita HE, HE NS, Si, IRUs, and MRUs from space activities, diagnostic x=ray
examihatiofis, and nuclear medicine procedures.
H E HE,N s S- IRU MRU MRU
Source (mSv) (mSv) (m_;v) (xl0-5)l (xl0-6)b (xl0-S)c
Space activities Y 1.51d 1.42 0.79 3.10 2.10 1.78
SEM 0.26 0.24 0.13 0.52 0.36 0.30
n=19
Diagnostic x-ray Y 15.86 13.09 10.95 37.94 22.73 16.38
examinations SEM 4.73 3.76 3.09 9.72 6.70 4.70
n=19
Nuclear medicine _" 3.58 4.05 2.24 6.80 4.92 5.08
procedures SEM 1.19 1.28 0.69 2.42 1.69 1.59
n=4
• IRU baaed on NCRP age- and sex-specific cancer incidence risk coefficients
in Table 1 (NCRP89).
b MRU baaed on NCRP age- and aax-lpecific cancer mortality rkk coefficientl
in Table 2 (NCRP89).
c MRU baaed on ICRP mortality rkk coefficients (ICRP77).
d Per capita radiation abeorbed dose (raCy) from TLD (LiF-100) waa 0.95 + 0.012 SEM.
Table 7. Per cent differences between various detriment estimators.
Percentage by
which estimator
differs from
Comparison comparison
Exposure Estimator estimator estimator
Space activities HE,NS HE -6
Sj HE -48
MRUNcRP IRUNoRP -32
MRUIcRP MRUNcRP - 17
Diagnostic x-ray HE,NS HE -17
examinations Sj HE - 31
MRUNcRp IRUNcRP -40
MRUIcRP MRUNcRP -28
Nuclear medicine HE,NS HE 13
procedures Sj HE -37
MRUNcRp IRUNcRP -28
MRUIcRP MRUNcRP 3
Table 8 lists in tabular notation values of the total per capita (nffil9) IRUs from space
activities, diagnostic X-ray, and nuclear medicine procedures, which were 3.1 x 10-5, 37.9 x 10-5,
and 6.8 x 10-5, respectively. The per capita IRU from medical procedures was 14 times greater
than IRU from space activities. This finding coincides with the marked difference between the
total per capita HE from medical procedures and HE from space activities. Per capita values of
MRUs from space activities, diagnostic X-ray, and nuclear medicine procedures were 2.1 x 10-5,
22.7 x 10-5, and 4.9 x 10-5, respectively. Similarly, the per capita MRU from medical procedures
was 13 times greater than that from space activities. The observed difference between cancer
incidence and mortality expressed by IRU and MRU was simply due to the site-specific
case-fatality ratios.
Figures 6,7, and 8 illustrate the per cent contributions of cancer incidence and mortality risk
from each tissue to the total risk for space activities, diagnostic X-ray, and nuclear medicine
procedures listed in Table 8. For uniform whole-body exposures from space activities (Figure 6),
the highest proportion of risk was for lung cancer, followed by leukemia, stomach, colon,
pancreas, and other organs that contributed approximately the same amount to total risk. Risks
for esophageal cancer were the lowest. Risks from diagnostic X-ray (Figure 7) were mainly from
cancer of the lung, other tissues, liver, thyroid, leukemia, colon, and kidney and bladder since
chest projections were the most frequent (43%). Skull (18%) and kidney-ureter-bladder (12%)
projections were the second and third most frequent. The highest contribution of risk from
nuclear medicine procedures (Figure 8) was from lung cancer borne out by its high risk (Tables 1
and 2). This was followed by leukemia, liver, and stomach cancer; the rest of the tissues
contributed approximately the same amount of risk to the total.
9
Table 8. Per capita (n=19) IRUs and MRUs from space activities,
diagnostic x-ray examinations, and nuclear medicine procedures.
Source
IRU x 10-s MRU x 10-5
Organ + SEM + SEM
Space activities (n=19) Lung .84 +. 14 .66 4-. 11
Thyroid .22 4- .04 .04 + .01
Esophagus .04 + .01 .03 4. .01
Stomach .27 + .05 .19 + .03
Colon .20 4. .04 .11 +_.02
Liver .11 + .02 .11 4. .02
Pancreas .15 + .03 .14 + .02
Kidney & Bladder .18 + .03 .06 + .01
Acute Leuk. .29 +_.05 .25 4. .04
Chron. Gran. Leuk. .14 + .02 .08 + .01
All other cancersa .21 4. .04 .08 4- .01
Total 3.10 + .52 2.10 + .36
Diagnostic x-ray
examinations (n=19)
Lung 12.72 +_ 3.76 10.01 +_
Thyroid 5.11 +_ .78 .82 +
Colon 2.62 4. 1.00 1.39 +
Liver 3.16 4. 1.32 3.07 +
Kidney & Bladder 2.50 4. .99 .77 +
Acute Leuk. 1.4 + .35 1.22 +
Chron. Gran, Leuk. .75 + .18 .45 +
All other cancers b 7.21 + 1.44 2.82 4.
Total 37.94 +_ 9.72 22.73 +
2.96
.12
.53
1.27
.30
.30
.11
.55
6.70
Nuclear medicine
procedures (n=4)
Other organs coneieted of the testes, brain,
Other organJ ¢ongi_t, ed of the testes, brain,
Lung 1.86 4. .71 1.45 + .56
Thyroid .28 +_. 13 .04 4- .02
Stomach .46 +. 17 .31 +_.12
Colon .29 + .12 .16 + .18
Liver .55 + .18 .55 4. .18
Pancreas .24 4- .07 .22 4- .06
Kidney & Bladder .32 + .12 .10 + .04
Acute Leuk. .83 4. .36 .78 + .31
Chron. Gran. Leuk. .41 +_.18 .25 4.. 10
All other cancersc .42 4.. 14 .16 + .06
Total 6.80 4. 2.42 4.92 4- 1.69
e Other organs eonalated of the tmtm, bone, and adrenals.
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Figure 3. Per cent contribution of weighted dose equivalents
to H_. for space activities (nffi20), diagnostic X-ray (nffi364),
and nuclear medicine procedures (nffi65).
CONCLUSIONS
EXPOSURES FROM SPACE ACTIVITIES
Over the years, there has been a steady accumulation of radiation-induced risk from space
activities. On the other hand, risks from medical procedures have increased at a much higher
rate. Notwithstanding this caveat, we consider risks from medical procedures only when dealing
with total risk, and accordingly, do not account for risk from medical procedures when comparing
an individual's cumulative lifetime risk to the 3% career risk limit. We believe that our approach
in using risk coefficients based on low-LET exposures from low-orbit space activities is justified
since the majority of dose is attributable to low-LET radiations, whose average quality factor is
1.2.
Manned space activities during Space Station Freedom and interplanetary travel will involve
radiation exposures that are much higher than those presently experienced on Shuttle (32). We are
vigorously pursuing methods for obtaining refined organ dose equivalents from known space
radiation environments in order to estimate the radiation-induced cancer and genetic risks to space
workers.
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HE,_s for space activities (n=20), diagnostic X-ray (n=364),
and nuclear medicine procedures (n-65).
EXPOSURES FROM MEDICAL PROCEDURES
We found that for x-ray examinations and radionuclide studies, HE overestimated detriment
when compared to Sj. Perhaps the most important finding was that HE,NS, based on the ICRP
somatic risk of 1.25 x 10-s Sv-1, underestimated the NCRP-based mortality risk for space
activities _d diagnostic X-ray and wceresfimated NCRP-based mortality iisk l_rorn radionuclide
studies. The remainder organs contributed the most to HE from diagnostic x-ray examinations
and nuclear medicine procedures.
These estimators, representing harm to an individual, are quantities whose values are affected
by several phenomena: (1) the type of exposure, i.e., internal or external, and the irradiation
geometry, (2) the sex and age distribution of the population that the individual represents, and (3)
the particular application of these quantities. In the present treatment, cause (1) dealt with whole
or partial-body exposures from multiple internal and external sources of radiation. Changes due
to cause (2) were fully taken into consideration by using ICRP weighting factors which are
averaged over sex and age. Cause (3) was also fully considered as we used these quantities to
estimate with some degree of accuracy the somatic risks to each space worker. The choice of
which parameter to use when assessing stochastic risk to an individual or population should be
based on several criteria. For the protection of workers in general, where justification of practice
12
and optimization of protection are paramount, emphasis is placed on HE in order to assess the
harm incurred by fatal cancers and hereditary damage in the first two generations. When
assessing the stochastic somatic risk to an individual, HE,NS, which does not account for genetic
risk, should be used. When the objective is to determine the lifetime cancer incidence and
mortality risks to various organs of an individual, we recommend use of site-specific IRUs and
MRUs that are based on age- and sex-specific lifetime incidence and mortality risk coefficients
such as those in Tables 1 and 2. In the present work, we found that the different estimators were
all within a factor of 2.
COMPARISON OF EXPOSURES FROM MEDICAL PROCEDURES TO SPACE ACTIVITIES
Calculations of the various detriment estimators confirm the impression that the risks to the
astronaut population from medical procedures is substantially higher than the risks incurred from
space activities. This was no surprise since space workers are more frequently exposed to medical
procedures for screening during selection and routine health care. A similar case could be made
for career aviators of all types. This trend will undoubtedly change in the future when astronauts
are exposed to increased levels of radiation during Space Station Freedom and exploratory missions
and more is known about the risks from exposure to high-LET radiation.
ESTIMATION OF LIFETIME RISKS
Risk estimates for human exposure to low doses of radiation in the range 0-.2 Gy (0- 20 rad)
are based upon observational data from radioepidemiological studies and are far from precise. An
equally important part of radiation risk estimation is the assumption about the underlying
dose-response relationship. At low doses, the dose-response assumptions are not known precisely
but based on reasonable assumptions given certain biophysical principles. This belief does not
recognize the fact that, in humans, radiatlon-induced cancers are masked by naturally occurring
(spontaneous) cancers and by the presence of genetic and host factors in the exposed individual.
Radiation risk estimates from low doses of radiation are at best uncertain.
In radiation protection, rationalizations of a dose-response relationship in the low dose region
are vital and justifiably used by assuming that, albeit small, there is a probability of induced
detectable harm. Unfortunately, several large analytical etiologic studies on cancer mortality in
the nuclear industry have found that the standardized mortality ratios (SMR) for leukemia and
solid cancers were all below unity, thus indicating that cancer mortality was lower in the exposed
population (33,34,35). Furthermore, Land has pointed out that studies on cancer in workers
exposed to low doses of radiation are a waste of time and money (36).
Studies on humans exposed to intermediate to very high doses of radiation in the range 0.2 -
5 Gy (20 - 500 tad), such as those of the atomic bomb survivors (37,3g,39), persons with
anklylosing spondylitis (40), and women undergoing radiation therapy for cervical cancer (41),
have shown the signal-to-noise ratio to be much higher allowing for a more reliable measure of
risk.
There were additional factors considered in the present analysis. While there is control over
the reduction of exposure from medical procedures, there is, aside from the use of time, distance,
and shielding, little control over the reduction of exposure from space activities. Further, there
are no radioepidemiological data for human exposure to space radiation from which risk can be
directly estimated. There are radiobiological data, however.
In view of these shortcomings, we have adopted the NCRP's system of risk limitation for the
purpose of establishing radiation protection guidelines for manned space activities. In addition,
we have established a program for assessing and monitoring these risks to counsel the astronauts.
The Soviets have begun similar work in their space program as required by their government
standards (42).
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Figure 5. Per cent contribution of weighted dose equivalents
to Sj for space activities (nffi20), diagnostic X-ray (n=364),
and nuclear medicine procedures (nffi65).
SUMMARY
Several problems were encountered in the course of this investigation. The first was that we
lacked a computerized anthropomorphic female model to estimate the dose to the breasts, ovaries,
and uterus from space activities. This imposed serious limitations on our ability to estimate
collective and per capita risks to female astronauts. Computerized anthropomorphic male and
female models based on more complete geometry data, such as that obtained with computerized
tomography or magnetic resonance imaging, need to be developed and maintained.
Finally, we realize that our approach in using the NCRP age- and sex-specific lifetime risk
coefficients to assign conservative risk estimates to workers who are exposed occupationally and
non-occupationally to low- and high-LET radiations involved the acceptance of some rather grave
assumptions. Nevertheless, as the uncertainties surrounding low-dose radiation risk estimates are
reduced and radiation risk information becomes more stable and reliable, NASA will be in a
position to adopt such information as it becomes available.
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APPENDIX
ESTIMATION OF INCIDENCE RISK UNITS (x 10-s) AND MORTALITY RISK UNITS (x 10-s)
PER mGy EXPOSURE FROM SPACE ACTIVITIES AND MEDICAL PROCEDURES
The following equation was used to calculate lifetime Incidence Risk Units (IRU x 10-s) for
organs listed in Table 1:
(1)
where IRUn is the incidence risk unit (x 10-5) for a given organ for new dose, Dn in mGy and
IRUT is the incidence risk unit (x 10-5) associated with dose, I>r in Table 1. Likewise, the the
lifetime Mortality Risk Unit from exposure to space radiation and medical procedures was
approximated by the equation
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Figure 7. Per cent contribution of individual tissue IRUs and MRUs to
total incidence and mortality risk from diagnostic X-ray (nffi364).
. MRUr ( D.1ff R U ,,
where IRU. is the mortality risk unit (x 10 -s) for a given organ for new dose, D. in mGy and
IRUT is the mortality risk unit (x 10-6) associated with dose, Dr in Table 2.
CALCULATION OF Hr., Hr.,Ns. AND Sj FROM SPACE ACTIVITIES AND MEDICAL
PROCEDURES
The Hr. from space activities and medical procedures to astronaut k was taken as
(2)
",'EE(H,,,'v,).
j i
(3)
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Figure 8. Per cent contribution of individual tissue IRUs and MRUs to
total incidence and mortality risk from nuclear medicine procedures (n=65).
where H E is the lifetime cumulative effective dose equivalent from space activities and medical
procedures for astronaut k, Hij k iS the dose equivalent to organ j from i exposures to medical
procedures for astronaut k, and WT is the ICRP weighting factor for organ j. Table 3 lists the
weighting factors used in Eq. 3.
The equation used for calculating the normalized somatic effective dose equivalent HB,_s from
space activities and medical procedures was
where H_.,NS is the somatic effective dose equivalent (normalized to 100% of the total somatic risk)
from space activities and medical exposures for astronaut k, Hijk iS the dose equivalent to organ j
from i exposures to space activities and medical procedures for astronaut k, and WT,NS is the
normalized somatic weighting factor for organ j, which are liSted in Table 3.
The weighted dose Sj from space activities and medical procedures iS defined by the form:
17
where riT/R are the ponderation factors listed in Table 4, HTijk is the dose equivalent to organ T
in the i age stratum for examination j, for astronaut k.
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